Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Aug;68(2):364–367. doi: 10.1038/bjc.1993.341

Interleukin-2 receptor and ovarian cancer.

O J Owens 1, C Taggart 1, R Wilson 1, J J Walker 1, J H McKillop 1, J H Kennedy 1
PMCID: PMC1968563  PMID: 8347492

Abstract

Interleukin-2 receptor (IL-2R) can be detected in serum. We estimated the IL-2R in the serum of 78 women, of whom 30 were diagnosed as having malignant ovarian tumours, five had non ovarian tumours, one had a negative second look laparotomy, 11 had benign ovarian tumours, three had uterine fibroids and 28 were age-matched controls. The results indicated that the serum IL-2R of these patients was significantly elevated in ovarian cancer patients compared to both controls (P < 0.0001) and benign ovarian tumours (P < 0.0002). There were no significant differences in IL-2R levels between stage of disease and degree of differentiation within the ovarian tumour group.

Full text

PDF
364

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fierro M. T., Lisa F., Novelli M., Bertero M., Bernengo M. G. Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study. Dermatology. 1992;184(3):182–189. doi: 10.1159/000247537. [DOI] [PubMed] [Google Scholar]
  2. Kikuchi Y., Kizawa I., Oomori K., Iwano I., Kita T., Miyauchi M., Kato K. Effects of cimetidine on interleukin-2 production by peripheral blood lymphocytes in advanced ovarian carcinoma. Eur J Cancer Clin Oncol. 1988 Jul;24(7):1185–1190. doi: 10.1016/0277-5379(88)90126-5. [DOI] [PubMed] [Google Scholar]
  3. Lauria F., Rondelli D., Raspadori D., Zinzani P. L., Benfenati D., Pileri S., Sabattini E., Tura S. Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment. Leuk Lymphoma. 1992 May;7(1-2):103–107. doi: 10.3109/10428199209053608. [DOI] [PubMed] [Google Scholar]
  4. Lotze M. T., Custer M. C., Sharrow S. O., Rubin L. A., Nelson D. L., Rosenberg S. A. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res. 1987 Apr 15;47(8):2188–2195. [PubMed] [Google Scholar]
  5. Mantovani G., Coiana A., Cossu F., Floris C., Proto E., Macciò A., Pisano G., Taglieri G., Puxeddu G., Del Giacco G. S. Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non-PHA-prestimulated cells in patients with cancer. Tumori. 1986 Aug 31;72(4):375–382. doi: 10.1177/030089168607200406. [DOI] [PubMed] [Google Scholar]
  6. Mills G. B., Paetkau V. Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (Interleukin 2). J Immunol. 1980 Nov;125(5):1897–1903. [PubMed] [Google Scholar]
  7. Mizel S. B. The interleukins. FASEB J. 1989 Oct;3(12):2379–2388. doi: 10.1096/fasebj.3.12.2676681. [DOI] [PubMed] [Google Scholar]
  8. Nakayama E., Asano S., Takuwa N., Yokota J., Miwa S. Decreased TCGF activity in the culture medium of PHA stimulated peripheral mononuclear cells from patients with metastatic cancer. Clin Exp Immunol. 1983 Mar;51(3):511–516. [PMC free article] [PubMed] [Google Scholar]
  9. Navarro D., Cabrera J. J., Falcón O., Jiménez P., Ruiz A., Chirino R., López A., Rivero J. F., Díaz-Chico J. C., Díaz-Chico B. N. Monoclonal antibody characterization of progesterone receptors, estrogen receptors and the stress-responsive protein of 27 kDa (SRP27) in human uterine leiomyoma. J Steroid Biochem. 1989;34(1-6):491–498. doi: 10.1016/0022-4731(89)90133-7. [DOI] [PubMed] [Google Scholar]
  10. Robb R. J., Munck A., Smith K. A. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med. 1981 Nov 1;154(5):1455–1474. doi: 10.1084/jem.154.5.1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rovelli F., Lissoni P., Crispino S., Barni S., Fumagalli G., Paolorossi F., Tancini G. Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori. 1988 Dec 31;74(6):633–637. doi: 10.1177/030089168807400603. [DOI] [PubMed] [Google Scholar]
  12. Shepherd J. H. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989 Aug;96(8):889–892. doi: 10.1111/j.1471-0528.1989.tb03341.x. [DOI] [PubMed] [Google Scholar]
  13. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  14. Waldmann T. A., Pastan I. H., Gansow O. A., Junghans R. P. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med. 1992 Jan 15;116(2):148–160. doi: 10.7326/0003-4819-116-2-148. [DOI] [PubMed] [Google Scholar]
  15. Wanebo H. J., Pace R., Hargett S., Katz D., Sando J. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer. 1986 Feb 1;57(3):656–662. doi: 10.1002/1097-0142(19860201)57:3<656::aid-cncr2820570343>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES